- Previous Close
0.2500 - Open
0.2400 - Bid 0.2250 x --
- Ask 0.2300 x --
- Day's Range
0.2200 - 0.2400 - 52 Week Range
0.0650 - 0.3500 - Volume
323,495 - Avg. Volume
461,251 - Market Cap (intraday)
22.172M - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0100 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Pharmala Biotech Holdings Inc., doing business as PharmAla, focuses on the developing, manufacturing, and commercializing of substituted methylenedioxy-phenethylamines (MDXX) active pharmaceutical ingredients. It also provides MDXX class compounds, such as 1,3-Benzodioxolyl-Nmethylbutanamine (MBDB); and 3,4-Methylenedioxy-N-ethylamphetamine (MDEA/MDE), as well as formulations of MDXX compounds. The company is headquartered in Vancouver, Canada.
pharmala.caRecent News: MDMA.CN
View MorePerformance Overview: MDMA.CN
Trailing total returns as of 12/27/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: MDMA.CN
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: MDMA.CN
View MoreValuation Measures
Market Cap
22.17M
Enterprise Value
21.75M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
19.68
Price/Book (mrq)
11.19
Enterprise Value/Revenue
21.01
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
--
Return on Equity (ttm)
--
Revenue (ttm)
--
Net Income Avi to Common (ttm)
--
Diluted EPS (ttm)
-0.0100
Balance Sheet and Cash Flow
Total Cash (mrq)
--
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
--